Methods to treat allergic conditions

Abstract

Disclosed are methods to treat allergic conditions, including pulmonary and non-pulmonary conditions, in a subject by administering a composition that inhibits Pim kinase. Also disclosed are methods to treat allergic conditions in a subject by administering a composition that induces expression of Runx3.

1 .- 17 . (canceled) 
     
     
         18 . A method to treat an allergic condition in a subject who has or is at risk of having an allergic condition, comprising administering to the subject a composition that induces expression of Runx3. 
     
     
         19 . The method of  claim 18 , wherein the allergic condition is selected from the group consisting of allergic rhinitis, asthma, airway hyperresponsiveness, airway inflammation, a food allergy, eosinophilic esophagitis, chronic urticaria, atopic dermatitis, occupational allergy, allergic conjunctivitis, hay fever, airborne allergic sensitivities, stinging insect allergy, hypersensitivity pneumonitis, eosinophilic lung diseases, inflammatory bowel disease, ulcerative colitis, and Crohn's disease. 
     
     
         20 . The method of  claim 18 , wherein the subject has been sensitized to an allergen and has been exposed to, or is at risk of being exposed to, the allergen. 
     
     
         21 . The method of  claim 18 , wherein the allergen is selected from the group consisting of a food, a plant, a gas, a pathogen, a metal, a glue and a drug. 
     
     
         22 . The method of  claim 18 , wherein the composition interacts with a regulator of Runx3 expression. 
     
     
         23 . The method of  claim 22 , wherein the regulator is selected from the group consisting of a Pim kinase, CxCL12, core binding factor-beta, transducin-like enhancer protein 1, IL-7, Stat 5, ETS-1 and IRF-4. 
     
     
         24 . The method of  claim 18 , wherein the composition inhibits the activity of a compound selected from the group consisting of IRF-4 and a Pim kinase. 
     
     
         25 . The method of  claim 24 , wherein the Pim kinase is selected from the group consisting of Pim1 kinase, Pim2 kinase and Pim3 kinase. 
     
     
         26 . The method of  claim 18 , wherein the composition comprises an IRF-4 inhibitor. 
     
     
         27 . The method of  claim 18 , wherein the composition comprises a Pim kinase inhibitor selected from the group consisting of Pim1 kinase inhibitor, Pim2 kinase inhibitor and Pim3 kinase inhibitor. 
     
     
         28 . The method of  claim 27 , wherein the Pim kinase inhibitor is selected from the group consisting of AR460770, AR440, SimI4A, staurosporine, and bisindolylmaleimide. 
     
     
         29 . The method of  claim 18 , wherein the composition activates the activity of a compound selected from the group consisting of CxCL12, core binding factor-beta, transducin-like enhancer protein 1, IL-7, Stat 5, and ETS-1. 
     
     
         30 . The method of  claim 29 , wherein the composition comprises an activator selected from the group consisting of G proteins, phosphatidylinositol-3 kinase (PI3K), JAK kinases, Rho GTPases, and focal adhesion-associated proteins. 
     
     
         31 . The method of  claim 18 , wherein the composition comprises a compound selected from the group consisting of a small molecule inhibitor, an antibody, a chemical entity, a nucleotide, a peptide and a protein. 
     
     
         32 .- 57 . (canceled) 
     
     
         58 . The method of  claim 18 , wherein the composition is administered by a delivery method selected from the group consisting of aerosol delivery, parenteral delivery and oral delivery.